Found on
Group by:
Title Date Type
Senate health package includes surprisingly aggressive drug pricing reforms
STAT News (05/23/19) Florko, Nicholas; Facher, Lev
Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA) on Thursday unveiled an unexpectedly ambitious plan to lower the price of prescription drugs. The draft legislation includes several proposals that have the potential to upend PBMs, such as banning spread pricing. The proposal would also mandate…
May 23, 2019 Publication Pharmacy Today Daily Edition
Pharm D Solutions issues voluntary recall of all sterile compounded drugs
FDA Recalls, Market Withdrawals, & Safety Alerts (05/23/19)
Pharm D Solutions announced a voluntary recall of all sterile compounded drug products within expiry due to concerns that practices at the pharmacy have the potential to pose a risk of contamination to products that are intended to be sterile. The concerns were raised following a routine inspection…
May 23, 2019 Publication Pharmacy Today Daily Edition
Indy 500 officials to offer measles vaccine at race
Associated Press (05/23/19)
Amid a growing number of measles cases in the United States this year, the medical director of the Indianapolis 500 said Thursday that some fans will be able get measles vaccines at the event. The race, which is expected to attract more than 275,000 fans, will be held this Sunday, May 26. According…
May 23, 2019 Publication Pharmacy Today Daily Edition
Long term tapering vs. standard prednisolone treatment for first episode of childhood nephrotic syndrome
BMJ (05/23/19) Vol. 365 Webb, Nicholas J.A.; Woolley, Rebecca A.; Lambe, Tosin; et al.
A multisite U.K. trial explored whether prolonging initial prednisolone treatment in children with idiopathic steroid sensitive nephrotic syndrome would improve outcomes in this patient population. The Phase III study included 237 patients aged 1–14 years who experienced their first episode…
May 23, 2019 Publication Pharmacy Today Daily Edition
Effects of antiplatelet therapy after stroke due to intracerebral hemorrhage
The Lancet (05/22/19) Al-Shahi Salman, R.; Dennis, M.S.; Murray, G.D.; et al.
U.K. researchers speculated that antiplatelet or anticoagulant therapy might safely and effectively lower the risk of major vascular events in adult survivors of intracerebral hemorrhage. They designed a prospective trial, called RESTART, and populated it with patients meeting this profile who…
May 23, 2019 Publication Pharmacy Today Daily Edition
Pharmacy among industries Amazon could disrupt
Drug Store News (05/23/19) Wilson, Marianne
A new CB Insights research brief outlines how Amazon will be a disruptive influence in the pharmacy industry as it works its way into the business of drug distribution. Amazon's 2018 acquisition of PillPack, a $100 million-plus business with pharmacy licenses in all 50 states represents its first…
May 23, 2019 Publication Pharmacy Today Daily Edition
FLAVORx now available at Walmart Neighborhood Markets
Chain Drug Review (05/23/19)
Walmart announced this week that it is offering FLAVORx with certain liquid prescriptions for no additional cost at its Neighborhood Market pharmacies. "We know our customers face a lot of challenges during the day and getting your child to swallow necessary medications shouldn't be one of them,"…
May 23, 2019 Publication Pharmacy Today Daily Edition
Ex-FDA commissioner goes back to biotech investing
Fierce Biotech (05/23/19) Adams, Ben
Former FDA Commission Scott Gottlieb, MD, will return to his former life science venture capital firm, New Enterprise Associates (NEA), the company announced this week. Gottlieb, who left the FDA in early April, will be a "special partner" at NEA. He previously spent about a decade there before…
May 23, 2019 Publication Pharmacy Today Daily Edition
Pharmacists phone home post-discharge
Pharmacy Practice News (05/23/19) Rosenthal, Marie
An Irish study found that having pharmacists make a series of follow-up phone calls to patients after hospital discharge achieved lower rates of readmission. Drawing from a 426-bed hospital in Northern Ireland, the study matched patients who received three pharmacist-led, post-discharge telephone…
May 23, 2019 Publication Pharmacy Today Daily Edition
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Reuters (05/22/19) Humer, Caroline
U.S. regulators are expected to decide this month whether or not to approve Novartis's onasemnogene abeparvovec (Zolgensma), a 1-time gene therapy for spinal muscular atrophy (SMA). Although the company originally said it expected to price the treatment in the $4 million to $5 million range,…
May 23, 2019 Publication Pharmacy Today Daily Edition